What should I pay attention to when using Senen Hydroxychloroquine Sulfate Tablets

Rheumatoid arthritis and chronic arthritis are both common diseases in life. Although the conditions of these diseases are not very serious, they will affect the patient's quality of life and work status. Many patients are using Synergy Hydroxychloroquine Sulfate Tablets for treatment, and Synergy Hydroxychloroquine Sulfate Tablets can also treat some skin lesions. So what should be paid attention to when using Synergy Hydroxychloroquine Sulfate Tablets?

First, what should we pay attention to when using Senen Hydroxychloroquine Sulfate Tablets? This product is used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, and skin lesions caused or aggravated by sunlight. Sarcoidosis, sarcoidosis, Boeck's sarcoid, Schaumann's benign lymphogranuloma, Besnier's pernio lupus, arthritis, systemic lupus erythematosus, rheumatoid arthritis, rheumatic arthritis, calcification of the skin. All patients should undergo an ophthalmological examination prior to initiating treatment with this product. Examination includes visual acuity, ophthalmoscope examination, central visual field, and color vision. Thereafter, inspections should be carried out at least once a year. Retinopathy is highly correlated with drug dose. When the maximum daily dose does not exceed 6.5 mg/kg body weight, the risk of retinal damage is low. However, exceeding the recommended daily dose will greatly increase the risk of retinal toxicity. The frequency of ophthalmological examinations should be increased in patients with the following conditions: Daily dose exceeds 6.5 mg/kg ideal body weight. Absolute body weight is used as a guide for dosing in obese patients. Leading to drug overdose. Renal insufficiency. The cumulative dosage exceeds 200g.

Second, the elderly. Impaired visual acuity. If visual impairment (visual sensitivity, color vision, etc.) occurs, the drug should be discontinued immediately and the patient should be closely observed for the progression of the abnormal condition. Even after treatment is stopped, retinopathy (and visual impairment) may progress. Patients who are taking medications that may cause adverse eye or skin reactions should use this product with caution. This product should also be used with caution in patients with liver or kidney disease, or those taking medications known to affect these organs, and in patients with severe gastrointestinal, neurological, and hematologic abnormalities. Plasma hydroxychloroquine levels should be estimated in patients with severe hepatic or renal impairment in order to adjust the dose.

What should be paid attention to when using Senen Hydroxychloroquine Sulfate Tablets? Although the risk of bone marrow suppression is very low, because anemia, aplastic anemia, agranulocytosis, leukopenia and thrombocytopenia have been reported, regular blood cell counts are recommended. If abnormalities are found, the product should be discontinued. Patients who are sensitive to quinine, those with glucose-6-phosphate dehydrogenase deficiency, those with porphyria cutanea tarda exacerbated by hydroxychloroquine, and those with psoriasis should also use this drug with caution because it appears to increase the risk of adverse skin reactions.